Antelope begins first-in-human study of PSMA-targeted fluorescent imaging agent

Antelope said enrollment and dosing are underway in a Phase 1/2 study of AS1986NS, its investigational fluorescent imaging agent for prostate cancer. The early human trial is testing safety and tumor-binding performance under an active FDA IND, a key step for the company’s cancer imaging platform.

Why it matters: - Antelope’s first-in-human study moves the company’s fluorescent radioligand platform from preclinical development into clinical testing. - The trial could help validate a PSMA-targeted imaging approach for prostate cancer, where clearer tumor visualization can support diagnosis and surgery. - The study is being run under an active U.S. Food and Drug Administration Investigational New Drug application.

What happened: - Antelope said enrollment and dosing are underway in a Phase 1/2 first-in-human study of AS1986NS. - AS1986NS is an investigational PSMA-targeted fluorescent imaging agent for prostate cancer. - The company made the announcement on Aug. 13, 2026. - Antelope is a New York-based clinical-stage biotechnology company developing targeted fluorescent radioligand technologies.

The details: - The study is evaluating the safety of AS1986NS. - Researchers are also assessing whether the agent selectively binds to PSMA-expressing prostate cancer cells and produces localized fluorescence. - Pathology will serve as the reference standard in the study. - AS1986NS is the lead clinical candidate from Antelope’s fluorescent radioligand platform. - The platform combines molecular targeting with fluorescence and is being developed for cancer imaging and treatment. - AS1986NS remains investigational and has not been approved by the U.S. Food and Drug Administration. - The safety and effectiveness of AS1986NS have not been established. - Antelope says its broader platform is being developed for cancer imaging, precision surgery and radioligand therapy. - More information is available on Antelope’s website.

Between the lines: - The company’s first clinical readout will matter because early studies are usually designed to show safety and proof of targeting, not clinical benefit. - The mention of pathology as the reference standard signals that Antelope is trying to show the fluorescent signal matches real tumor tissue. - Amy Wu, Antelope’s founder and CEO, said bringing the first clinical candidate into human evaluation represents years of work. - Wu also thanked the patients, investigators and clinical teams involved in the study.

What’s next: - Antelope is likely to use early study data to determine whether AS1986NS should move into larger clinical trials. - Future results will help show whether the agent can advance toward imaging and potential treatment applications. - Antelope’s forward-looking statements indicate the company is also pursuing regulatory, research, development and commercialization activities.

The bottom line: - Antelope has crossed into human testing, and the next question is whether AS1986NS can prove safe and accurately light up prostate cancer tumors.